VPT:CC - Ventripoint to Sponsor the Annual Meeting of the British Congenital Cardiac Association
(TheNewswire)
Toronto, Ontario – TheNewswire –November 4, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that it will be a goldsponsor for the 2022 Annual Scientific Meeting of the BritishCongenital Cardiac Association (BCCA). Dr. Gregory Skinner, aClinical Advisor to the Company, will be giving a presentation thatwill highlight the use of the VMS+3.0 in retrieving volumetric andfunctional data for managing cardiac heart disease patients.
The meeting will take place on Monday 7 th and Tuesday8 th of November 2022 at the International Conference Centre in Birmingham,UK. The BCCA meeting attracts over 400 delegates from across the UKand worldwide with a focus in adult and paediatric congenitalcardiology. The attendees will be members of various cardiacassociations and health care professionals, which each year creates avaluable networking experience.
Dr. Skinner’s presentation will take place onNovember 8 th , 2022 and is entitled: “Accurate, Reproducible Volumetricand Functional Data for Managing Congenital Heart Disease Using VMSFrom Ventripoint”. The presentation will focus on the uniqueabilities of the VMS+3.0 in the management of congenital cardiacpatients through case studies and real-life examples.
Exhibiting at the BCCA meeting continuesVentripoint’s ongoing efforts to make the cardiology community awareof the benefits of the VMS+3.0 and allow them to have a hands-onexperience of the ease of use of the system in the exhibition boothand then schedule an on-site demonstration at their clinic.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.